Ipca Laboratories has entered into a partnership with BioSimilar Sciences PR LLC (BSS), US, to focus on a next-generation monoclonal antibody biosimilar targeting cancer and autoimmune diseases. Ipca will transfer late-stage development, clinical manufacturing, and commercial supply to BSS’ 200,000 sq. ft facility in Puerto Rico.

Lupin has received tentative approval from the US health regulator for the generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat the human immunodeficiency virus (HIV) infection.

Glenmark Specialty SA, subsidiary of Glenmark Pharmaceuticals, has signed an exclusive licence and collaboration pact with Hengrui Pharma for development and commercialisation of Trastuzumab Rezetecan, that is aimed at treating different type

See Full Page